Kliniska studier vid Tema Cancer

SECAR-studien. Part I: A study of MTD of Sodium selenite in patients with advanced carcinoma. A phase I study.Amendment 4: continuous treatment

Mattias Hedman

MASTIFF. MASTIFF MTH1, A phase I, Study on Tumors Inhibition, First in human, First in class

Jeffrey Yachnin

BoB. Basket of Baskets: A Modular, Open-label, Phase II, Multicentre Study To Evaluate Targeted Agents in Molecularly Selected Populations With Advanced Solid Tumors

Luigi de Petris

PSFF STUDIE- Blodburna vävnadsprov. Screening-program med blodburna vävnadsprov för patienter med avancerad cancer - PSFF studie

Jeffrey Yachnin

Keynote-587. A multicenter, open label, phase III extension trial to study the long-term safety and efficacy in participants with advanced tumors who are currently on treatment or in follow-up in a pembrolizumab trial.

Jeffrey Yachnin

BI-1206-03 MonKey. Phase 1/2a Clinical Trial of BI-1206, a Monoclonal Antibody to CD32b (FcγRIIB), in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors Previously Treated with Anti-PD1 or Anti-PDL1 Antibodies

Jeffrey Yachnin

Spencer-study. A phaSe 1/2 trial of EO2401, a novel microbial-derived Peptide therapeutic vaccine, in combination with PD-1 check point blockadE, for treatment of patients with locally advaNced or metastatic adrenocortical Carcinoma, or malignant phEochromocytoma/paRaganglioma

Jeffrey Yachnin

Navigate. A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib in Subjects with NTRKFusion-Positive Tumours

Jeffrey Yachnin

BIKUPAN (19-BI-1808-01). Phase 1/2a Open-Label, Dose-Escalation, Multicenter, First-in-Human, Consecutive-Cohort, Clinical Trial of BI-1808, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2), as a Single Agent and in Combination with Pembrolizumab in Subjects with Advanced Malignancies

Jeffrey Yachnin

ONCORELLA-1 (ONC001-CL-001). A phase I/II, open label, single arm study on safety, tolerability and anti-tumour efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal cell carcinoma

Jeffrey Yachnin

MCLA-128-CL01 eNRGy. A Phase I/II Study of MCLA-128, a full length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients with Solid Tumors

Jeffrey Yachnin

CCS1477-02. An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy in patients with hematological malignancies

Maria Creignou

FIRST (RLY-4008-101). A First-in-Human Study of Highly Selective FGFR2 Inhibitor,RLY-4008, in Patients With Intrahepatic Cholangiocarcinoma (ICC) and Other Advanced Solid Tumors

Jeffrey Yachnin

iPCM. iPCM - implementation of Personalised Cancer Medicine

Jeffrey Yachnin

Cloudin-6 BNT211-01. Phase I/IIa, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-positive relapsed or refractory advanced solid tumors

Stephan Mielke

CERTIS1. A Modular Phase I/IIa, Open-label, Multi-centre Study to Assess the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD) and Preliminary Efficacy of Ascending Doses of AZD9574 as Monotherapy and in Combination with Anti-cancer Agents in Patientswith Advanced Solid Malignancies (CERTIS1)

Theodoros Foukakis

NeoGap (NEOGAP-CRC-01). A First-In-Human, Phase I/IIa Trial of the novel T cell Immunotherapy pTTL in Patients with Advanced Colorectal Cancer

Maximilian Kordes

ALPHAVILLE (SGNALPV-001). Phase 1 Study of SGN-ALPV in Advanced Solid Tumors

Jeffrey Yachnin

FORE (F8394-201). A Phase 2 Master Protocol to assess the efficacy and safetyof FORE8394, an inhibitor of BRAF class 1 and class 2alterations, in participants with cancer harboring BRAFalterations

Jeffrey Yachnin

BIWAC (BI 1403-0001- Brightline). A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 in patients with advanced or metastatic solid tumors

Christina Linder Stragliotto